The DOI matches its Crossref record.
The Treatment of Bleeding in Acquired Haemophilia with Recombinant Factor VIIa: A Multicentre Study
Abstract
Summary: Recombinant factor Vila was used to treat 38 patients with acquired haemophilia participating in the Novoseven compassionate-use program. 19 were male, median age 59, range 2-89 years. The median pre-treatment anti-human (H) and anti-porcine (P) inhibitor titre was H 43 BU/ml (range 1-4500) and P 4.5 BU/ml (range 0-1600). Recombinant factor VIIa was used as first-line therapy for 14 bleeding episodes and as salvage-therapy for 60 episodes which failed to respond to blood-product therapy given for a median of four days (range 1-21 days) prior to treatment with rVIIa. Pre-rVIIa treatment was not reported for four episodes. The indications for treatment were 7 haemarthroses, 40 muscle haematomas, 20 urinary or GI haemorrhages and 3 surgical interventions. The median starting dose of rVIIa was 90.4 ug/kg (range 45-181). A median of 28 doses (range 1-541) were given per episode, over a median 3.9 days (range 0-43). Efficacy was assessed clinically 8 and 24 h after the start of rVIIa and at the end of treatment. A good response was obtained in all 14 bleeds for which rVIIa was used as first-line therapy. The response after 24 h of rVIIa salvage-therapy for 60 bleeds was good in 75%, partial in 17% and poor in 8%. Efficacy was unreported in 4 cases. The median prothrombin time (PTT) shortened from 12 s (range 9.3-20) pre-treatment to 8.8 s (range 6-14) during treatment. The clinical response did not correlate with the dose of rVIIa used, the type of bleed or the degree of shortening of the PTT following rVIIa infusion. Three patients died from haemorrhagic complications of acquired haemophilia. This mortality of 7.9% is lower than previously reported for this condition. Although one patient developed DIC during treatment with rVIIa, this was probably attributable to hypovolaemic shock, massive transfusion and the use of PCCs. This study demonstrates that rVIIa is a safe, useful and effective treatment for bleeding in patients with acquired haemophilia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Acquired Haemophilia: Review and Meta‐Analysis Focused on Therapy and Prognostic Factors
Delgado, J., Jimenez‐Yuste, V., Hernandez‐Navarro, F., & Villar, A. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04162.x · Cited by 469
International recommendations on the diagnosis and treatment of patients with acquired hemophilia A
Huth-Kuhne, A., Baudo, F., Collins, P., Ingerslev, J., Kessler, C. M., Levesque, H., Castellano, M. E. M., Shima, M., & St-Louis, J. (2009) · Haematologica · doi:10.3324/haematol.2008.001743 · Cited by 433
Baudo, F., Collins, P., Huth-Kühne, A., Lévesque, H., Marco, P., Nemes, L., Pellegrini, F., Tengborn, L., & Knoebl, P. (2012) · Blood · doi:10.1182/blood-2012-02-408930 · Cited by 386
Aledort, L., Beardsley, D., Cooper, H., Davignon, G., Ewenstein, B., Gilchrist, G., Gill, J., Glader, B., Hoots, W. K., Kisker, C. T., et al. (1998) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615388 · Cited by 354
Bijsterveld, N. R., Moons, A. H., Boekholdt, S. M., van Aken, B. E., Fennema, H., Peters, R. J. G., Meijers, J. C. M., Büller, H. R., & Levi, M. (2002) · Circulation · doi:10.1161/01.cir.0000038501.87442.02 · Cited by 316
Metadata
- Authors
- Hay, C. R. M., Negrier, C., & Ludlam, C. A.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 1997
- Volume
- 78
- Issue
- 06
- Pages
- 1463-1467
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W69280588
- Cited by
- 344
- References
- 0
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Treatment of Bleeding in Acquired Haemophilia with Recombinant Factor VIIa: A Multicentre Study. https://app.cochat.ai/papers/10.1055/s-0038-1665434
- The paper
- Hay, C. R. M., Negrier, C., & Ludlam, C. A. (1997). The Treatment of Bleeding in Acquired Haemophilia with Recombinant Factor VIIa: A Multicentre Study. Thrombosis and Haemostasis. https://doi.org/10.1055/s-0038-1665434
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.